NASDAQ:AKAOAchaogen Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Achaogen Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Share Today's Range N/A50-Day Range$0.11MA: $0.11▼$0.1152-Week Range N/AVolumeN/AAverage Volume3.34 million shsMarket Capitalization$7.03 millionP/E RatioN/ADividend YieldN/ABeta0.78 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Achaogen, Inc., a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae; and therapeutic antibody discovery program. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited to manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Achaogen. Previous Next 3.2 Community Rank Outperform VotesAchaogen has received 479 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAchaogen has received 278 “underperform” votes. (Add your “underperform” vote.)Community SentimentAchaogen has received 63.28% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Achaogen and other stocks. Vote “Outperform” if you believe AKAO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AKAO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAchaogen does not currently pay a dividend.Dividend GrowthAchaogen does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Achaogen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.80% of the stock of Achaogen is held by insiders.Percentage Held by InstitutionsOnly 31.85% of the stock of Achaogen is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Achaogen are expected to grow in the coming year, from ($1.27) to ($0.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Achaogen is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Achaogen is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 0.0Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.77 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AKAO Previous Symbol CUSIPN/A CIK1301501 Webwww.achaogen.com Phone650-800-3636Debt Debt-to-Equity Ratio1.00 Current Ratio0.78 Quick Ratio0.77Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$8.73 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.13) per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)($3.70) Net Income$-186,510,000.00 Net Margins-2,136.94% Return on Equity-357.49% Return on Assets-127.68%Miscellaneous Employees206 Outstanding Shares63,880,000Market Cap$7.03 million Next Earnings DateN/A OptionableOptionable Receive AKAO News and Ratings via Email Sign-up to receive the latest news and ratings for AKAO and its competitors with MarketBeat's FREE daily newsletter. Achaogen (NASDAQ:AKAO) Frequently Asked Questions How were Achaogen's earnings last quarter? Achaogen Inc (NASDAQ:AKAO) announced its quarterly earnings results on Monday, August, 6th. The biopharmaceutical company reported ($1.11) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.92) by $0.19. The biopharmaceutical company earned $2.56 million during the quarter, compared to the consensus estimate of $1.49 million. Achaogen had a negative net margin of 2,136.94% and a negative return on equity of 357.49%. View Achaogen's earnings history. Has Achaogen been receiving favorable news coverage? Media stories about AKAO stock have trended negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Achaogen earned a news impact score of -2.7 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutAchaogen. Who are some of Achaogen's key competitors? Some companies that are related to Achaogen include Dare Bioscience (DARE), Spring Bank Pharmaceuticals (SBPH), Correvio Pharma (CORV), Sernova (SEOVF), Alimera Sciences (ALIM), Neurotrope (NTRP), Edesa Biotech (EDSA), Cyclacel Pharmaceuticals (CYCC), Jaguar Health (JAGX), AEterna Zentaris (AEZS), Pharmaxis (PXSLY), AzurRx BioPharma (AZRX), Eyegate Pharmaceuticals (EYEG), Innovate Biopharmaceuticals (INNT) and Aileron Therapeutics (ALRN). View all competitors. What other stocks do shareholders of Achaogen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Achaogen investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Associated British Foods (ABF), Chaarat Gold (CGH), AMC Entertainment (AMC), First Data (FDC), Synergy Pharmaceuticals (SGYP), Cypress Semiconductor (CY) and Apollo Global Management (APO). Who are Achaogen's key executives? Achaogen's management team includes the following people: Mr. Blake Wise, CEO & Director (Age 48)Mr. Gary Loeb, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 49)Ms. Zeryn Sarpangal, CFO and Principal Financial & Accounting Officer (Age 39)Ms. Elizabeth Bhatt, Chief Bus. Officer & COO (Age 50)Ms. Jeannie Lloyds, VP of Sales What is Achaogen's stock symbol? Achaogen trades on the NASDAQ under the ticker symbol "AKAO." How big of a company is Achaogen? Achaogen has a market capitalization of $0.00 and generates $8.73 million in revenue each year. The biopharmaceutical company earns $-186,510,000.00 in net income (profit) each year or ($3.70) on an earnings per share basis. Achaogen employs 206 workers across the globe. What is Achaogen's official website? The official website for Achaogen is www.achaogen.com. How can I contact Achaogen? Achaogen's mailing address is 1 TOWER PLACE SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-800-3636 or via email at [email protected] This page was last updated on 5/26/2020 by MarketBeat.com Staff
